Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma

Autor: Pepijn van Houten, James Nagarajah, Janneke E W Walraven, Martin Jaeger, Adriana C H van Engen-van Grunsven, Johannes W Smit, Romana T Netea-Maier

Publikováno v: European Thyroid Journal, Vol 13, Iss 4, Pp 1-9 (2024)

Objective: Patients with non-medullary thyroid carcinoma (NMTC) that are refractory to radioactive iodine (RAI) have a poor prognosis. Strategies for restoring the ability to take up iodine, so-called redifferentiation, are promising but not suitable

Externí odkaz: https://doaj.org/article/8b42edffa11040c7b13500980dea3948

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Autor: Kalijn F. Bol, Gerty Schreibelt, Martine Bloemendal, Wouter W. van Willigen, Simone Hins-de Bree, Anna L. de Goede, Annemiek J. de Boer, Kevin J. H. Bos, Tjitske Duiveman-de Boer, Michel A. M. Olde Nordkamp, Tom G. M. van Oorschot, Carlijn J. Popelier, Jeanne M. Pots, Nicole M. Scharenborg, Mandy W. M. M. van de Rakt, Valeska de Ruiter, Wilmy S. van Meeteren, Michelle M. van Rossum, Sandra J. Croockewit, Bouke J. Koeneman, Jeroen H. A. Creemers, Inge M. N. Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A. van der Veldt, Dirk J. van Grünhagen, Johanna E. M. Werner, Johannes J. Bonenkamp, John B. A. G. Haanen, Marye J. Boers-Sonderen, Rutger H. T. Koornstra, Martijn F. Boomsma, Erik H. J. Aarntzen, Martin Gotthardt, James Nagarajah, Theo J. M. de Witte, Carl G. Figdor, Johannes H. W. de Wilt, Johannes Textor, Jan Willem B. de Groot, Winald R. Gerritsen, I. Jolanda M. de Vries

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)

Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were r

Externí odkaz: https://doaj.org/article/245269452ff04a81b46a9a6846fb6516

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation

Autor: Steffie M. B. Peters, Maaike C. T. Mink, Bastiaan M. Privé, Maarten de Bakker, Frank de Lange, Constantijn H. J. Muselaers, Niven Mehra, J. Alfred Witjes, Martin Gotthardt, James Nagarajah, Mark W. Konijnenberg

Publikováno v: EJNMMI Research, Vol 13, Iss 1, Pp 1-10 (2023)

Abstract Background Dosimetry in [177Lu]Lu-PSMA therapy is a valuable tool to assess treatment efficacy and toxicity. This study aims to develop a clinically implementable protocol to determine the absorbed dose in organs and tumor lesions after [177

Externí odkaz: https://doaj.org/article/3cddee000ded4238802511c9b9319d05

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Autor: Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah

Publikováno v: BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)

Abstract Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastati

Externí odkaz: https://doaj.org/article/05ea3477df904c7e9eba15f0eafa2c79

Fibroblast activation protein-targeted radionuclide therapy

Autor: Bastiaan M. Privé, Mohamed A. Boussihmad, Bart Timmermans, Willemijn A. van Gemert, Steffie M. B. Peters, Yvonne H. W. Derks, Sanne A. M. van Lith, Niven Mehra, James Nagarajah, Sandra Heskamp, Harm Westdorp

Publikováno v: European Journal of Nuclear Medicine and Molecular Imaging, 50, 1906-1918
European Journal of Nuclear Medicine and Molecular Imaging, 50, 7, pp. 1906-1918

Introduction Fibroblast activation protein (FAP) is highly overexpressed in stromal tissue of various cancers. While FAP has been recognized as a potential diagnostic or therapeutic cancer target for decades, the surge of radiolabeled FAP-targeting m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c823be3dbe81099db7fff15f27aff7a
http://www.scopus.com/inward/record.url?scp=85148534891&partnerID=8YFLogxK